Billy Yang

Billy Yang has extensive work experience in the biopharmaceutical industry. In 2006, they worked as a Research Associate II at Genitope Corporation, where they focused on antibody production, purification, and analysis. Billy optimized methods for generating Fab fragments and determining binding constants for antibody interactions. At Genentech, from 2008 to 2009, they worked as a Research Associate in the Analytic Process Department.

From 2009 to 2012, Billy Yang worked as a Senior Research Associate at Henlius Biopharmaceuticals, Inc., optimizing bioreactor runs for mAbs expressed in CHO cells. Billy achieved high IgG production levels. At Aragen Bioscience, from 2011 to 2017, they provided CRO downstream bio-production services, including protein purification using various techniques.

From 2017 to 2021, Billy Yang worked as an Associate Scientist at Sutro Biopharma, Inc., where they developed and established capturing chromatography methods for cytokine drug candidates. Billy also worked on generating GLP/Tox material at a large scale.

More recently, in 2021, Billy Yang joined CytomX Therapeutics as a Scientist, where they optimized a PhIII mAb downstream process and supported late-stage development activities. Billy also investigated viral clearance restoration using a Surrogate MockV-MVM kit.

Billy Yang's most recent role is as a Senior Scientist at GigaGen Inc, starting in 2022.

Billy Yang's education history includes a Bachelor of Science (BS) degree in Genetics & Genetic Engineering from Fudan University. Additionally, they pursued a Master's degree (MS) in Biochemistry & Molecular Biology at the Medical University of Ohio at Toledo. The specific start and end years for both degrees are not provided.